@charles_debock

No longer active on this platform. Please see me at alternative where sky is blue. Same handle.

 Sydney, Australia
bit.ly/3zxhpW6
Joined September 2017
  • Tweets955
  • Following466
  • Followers647
63Media
Like so many others, I have migrated to the other platform. Same profile name. Come and join us. I will slowly drop off from here. See you on the other side where the sky is blue.
4
372
FDA approves the Menin inhibitor revumenib for acute leukemia with a KMT2A translocation fda.gov/drugs/resources-info…
2
9
43
2,901
A link between the activity of a lineage-specific transcription factor PU.1 and epigenetic modulators mediating the response to glucocorticoids in acute lymphoblastic leukemia @charles_debock @KidsCancerInst @BridgeKatherine @AndrewHolding @UniOfYork @UNSW nature.com/articles/s41467-0…
1
6
1
17
5,249
Following our publication on T-ALL this week, pleased to share another paper from our group now published in @NatureComms linking PU.1 to glucocorticoid sensitivity in B-ALL rdcu.be/dZB01 which was a massive team effort @KidsCancerInst ; 🧵n/8 below
6
5
1
32
2,716
more replies
🧵7/8: So working with @SamuelJohnTayl1 we found that GR-LSO's were enriched for the A/T-Rich motif and then found that in a Dex-resistant cell line, Dex+DB2313 increased sensitivity. There is lots more data in the paper for you to explore, so check it out rdcu.be/dZB01
2
1
234
🧵8/8: This truly collaborative effort involved groups from China, USA, UK, and Australia and funding from @nhmrc @thekca @UNSW @BBSRC @ISEH enrichment grant, Perpetual IMPACT fund alongside many others as we seek to improve outcomes for children with ALL @KidsCancerInst
1
412
Charles de Bock retweeted
Hansson Lab@HanssonLab5 Nov 2024
Registration for the ISEH Ask the PIs event is open for trainees! Attend this networking event to connect with me and other PIs on career advancement and insight to navigating your path to independence. iseh.org/page/2024NICAsktheP… @ISEHSociety
6
10
792
Developing targeted therapies for children diagnosed with T-ALL and especially those who relapse are essential to improve outcomes. I am pleased to share our work, now published @BloodCancerJnl that describes a new AKR1C3 activated prodrug: Thread👇🧵rdcu.be/dZh70
4
10
32
2,051
more replies
Final massive thank you to the patients and families who have been part of the #ZeroChildhoodCancer program and continue to support critical research as we seek to cure all children with cancer.
1
137
🧵
119
Load more